Catalent Inc
NYSE:CTLT
Intrinsic Value
The intrinsic value of one
CTLT
stock under the Base Case scenario is
80
USD.
Compared to the current market price of 64.27 USD,
Catalent Inc
is
Undervalued by 20%.
The Intrinsic Value is calculated as the average of the two valuation methods:
Fundamental Analysis
CTLT Profitability Score
Profitability Due Diligence
Catalent Inc's profitability score is 51/100. The higher the profitability score, the more profitable the company is.
Score
Catalent Inc's profitability score is 51/100. The higher the profitability score, the more profitable the company is.
CTLT Solvency Score
Solvency Due Diligence
Catalent Inc's solvency score is 38/100. The higher the solvency score, the more solvent the company is.
Score
Catalent Inc's solvency score is 38/100. The higher the solvency score, the more solvent the company is.
Balance Sheet Decomposition
Catalent Inc
| Current Assets | 2.9B |
| Cash & Short-Term Investments | 470M |
| Receivables | 1.4B |
| Other Current Assets | 1B |
| Non-Current Assets | 8.2B |
| PP&E | 3.6B |
| Intangibles | 4.3B |
| Other Non-Current Assets | 390M |
| Current Liabilities | 1.5B |
| Accounts Payable | 367M |
| Accrued Liabilities | 318M |
| Other Current Liabilities | 841M |
| Non-Current Liabilities | 4.7B |
| Long-Term Debt | 4.2B |
| Other Non-Current Liabilities | 488M |
CTLT Capital Structure
Catalent Inc
| Market Capitalization | 11.6B USD | |
| Total Debt | 4.2B USD | |
| Minority Interest | 0 USD | |
| Preferred Equity | 0 USD | |
| Cash and Equivalents | 442M USD | |
| Short-Term Investments | 28M USD | |
| Enterprise Value | 15.3B USD | |
Wall St
Price Targets
CTLT Price Targets Summary
Catalent Inc
According to Wall Street analysts, the average 1-year price target for
CTLT
is 80.5 USD
with a low forecast of 55.55 USD and a high forecast of 94.5 USD.
Ownership
CTLT Insider Trading
Buy and sell transactions by insiders
During the last 12 months Catalent Inc insiders have not bought any shares, and sold 10.5M USD worth of shares. The last transaction was made on Mar 25, 2023 by Hopson Ricky (Pres. Clinical Dev Supply Div), who sold 31.7k USD worth of CTLT shares.
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
31.7k
USD
|
N/A
|
-31.7k
|
| 6 Months |
305k
USD
|
N/A
|
-305.5k
|
| 9 Months |
10M
USD
|
N/A
|
-10M
|
| 12 Months |
10.5M
USD
|
N/A
|
-10.5M
|
Shareholder Return
CTLT Return Decomposition
Main factors of price return
Market capitalization of
CTLT
shares
increased
by
114.23%
over the past 5 years.
The primary factor behind the change was
an increase
in earnings growth from
62.7M
to
409M, leading to a
growth
in the market capitalization of Catalent Inc by 281.18%.
Market capitalization of
CTLT
shares
increased
by
114.23%
over the past 5 years.
The primary factor behind the change was
an increase
in earnings growth from
62.7M
to
409M, leading to a
growth
in the market capitalization of Catalent Inc by 281.18%.
CTLT Price
Catalent Inc
| Average Annual Return | 40.67% |
| Standard Deviation of Annual Returns | 52.24% |
| Max Drawdown | -71% |
| Market Capitalization | 11.6B USD |
| Shares Outstanding | 181 000 000 |
| Percentage of Shares Shorted | 2.23% |
Company Profile
Catalent Inc
Country
Industry
Market Cap
Dividend Yield
Description
Catalent, Inc. is a holding company, which engages in the provision of delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products. The company is headquartered in Somerset, New Jersey and currently employs 17,300 full-time employees. The company went IPO on 2014-07-31. Its segments include Softgel and Oral Technologies, Biologics, Oral and Specialty Delivery, and Clinical Supply Services. The Softgel and Oral Technologies segment is engaged in providing formulation, development, and manufacturing services for soft capsules, as well as largescale manufacturing of oral solid dose forms. The Biologics segment provides biologic cell-line, cell therapy and viral vector gene therapy development and manufacturing services. The Oral and Specialty Delivery segment provides formulation development and manufacturing across a range of technologies along with integrated downstream clinical development and commercial supply solutions. The Clinical Supply Services segment is engaged in manufacturing, packaging, distribution and inventory management for drugs and biologics in clinical trials.
Contact
IPO
Employees
Officers
The intrinsic value of one
CTLT
stock under the Base Case scenario is
80
USD.
Compared to the current market price of 64.27 USD,
Catalent Inc
is
Undervalued by 20%.
